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Abstract
Background: Licorice flavonoid oil (LFO) has been reported to minimize visceral adipose tissue gain in obese mice
and to result in a decrease in body weight and body fat in humans; the effects of which may be more
pronounced when administered in an overfed state.
Methods: We investigated the effects of LFO in two separate studies. Study 1 included a sample of overweight or
grade I-II obese men and women (N = 22) who followed their usual dietary and physical activity programs. Study 2
included a sample of athletic men who followed their usual dietary and physical activity programs but consumed a
daily supplemental meal (25% above daily energy requirements) in an attempt to induce a state of overfeeding. In
both studies, subjects were randomly assigned (double-blind) to either LFO or a placebo for eight weeks, and
anthropometric and multiple biochemical outcomes (e.g., markers of oxidative stress, markers of insulin sensitivity,
blood lipids, etc.) were obtained before and following the intervention.
Results: No differences of statistical significance were noted between LFO and placebo for any measured variable
in Study 1 or Study 2. When investigating the percent change from baseline for data in Study 2, although not of
statistical significance, subjects in the LFO condition experienced less overall fat gain, as well as attenuation in the
elevation in selected blood lipids (e.g., cholesterol, LDL-C, and triglycerides).
Conclusion: These combined data indicate little effect of LFO supplementation within a sample of overweight/
obese men and women or athletic men, with the possible exception of attenuation in body fat gain and selected
components of the blood lipid panel in response to an overfeeding condition.
Background
Licorice flavonoid oil (LFO) has been reported to mini-
mize body weight and visceral adipose tissue gain in
obese mice [1,2], and to result in a decrease in body
weight and body fat in humans [3]. However, human
studies to date have focused primarily on anthropo-
metric outcomes (e.g., abdominal fat assessment via
computed tomography [CT] scans), while also including
measures of blood glucose and lipids. No human study
has included other important biomarkers of metabolic
and cardiovascular health such as adiponectin, resistin,
C-reactive protein, and measures of oxidative stress and
antioxidant capacity.
Licorice flavonoid oil has been studied for its mechan-
istic actions associated with reduction of abdominal fat
[4]. Specifically, LFO has been shown to possess nutrige-
nomic properties that effect cellular pathways with
regards to decreasing the mRNA levels of rate-limiting
enzymes involved in the hepatic fatty acid synthetic
pathway, while increasing the mRNA levels of a rate-
limiting enzyme in the hepatic fatty acid oxidative path-
way. Honda and colleagues suggest that a decrease in
abdominal adipose tissue weight may be mediated by
the transcriptional regulation of SREBP-1c and PPAR-
alpha in the liver [4]. Aside from the potential effects of
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ponent of the licorice root, glabridin, has been shown to
have antioxidant properties [5], which may assist in
attenuating lipid peroxidation.
DNA microarray analysis indicates that the effects of
LFO are specific to the genes involved in the regulation of
lipid metabolism [1], and that the effects may be most pro-
nounced when the supplement is taken with a meal; in
particular a meal rich in dietary fat. Therefore, it is possi-
ble that LFO supplementation during periods of overfeed-
ing may be helpful in attenuating the typical gain in body
weight/fat, as well as the rise in circulating blood lipids.
Considering the above, we undertook two separate
pilot studies to investigate the effect of LFO supplemen-
tation on anthropometric and biochemical markers of
health and adiposity. The first study included recreation-
ally active men and women who were overweight or
grade I-II obese (body mass index (BMI): 25.0-36.0
kg·m
-2) and followed their usual dietary and physical
activity programs. The second study included athletic
(i.e., resistance trained) men in very good physical
condition, who also followed their usual dietary and
physical activity programs but consumed a daily supple-
mental meal in an attempt to induce an acute state of
overfeeding. In both studies, subjects were randomly
assigned to either LFO or a placebo for a period of eight
weeks, and outcome measures were obtained before and
following the intervention.
Methods and Procedures
Subjects
For Study 1, 22 recreationally active men or women
(2-4 days per week of moderate exercise) between the
ages of 20 and 53 years participated. Subjects were over-
weight or grade I-II obese based on BMI classification.
For Study 2, 23 athletic men between the ages of 19 and
35 years participated. For both studies, subjects were
nonsmokers and did not have any cardiovascular, meta-
bolic, or orthopedic problems that might affect their
ability to perform exercise. Health history, drug and
dietary supplement usage, and physical activity question-
naires were completed by all subjects to determine elig-
ibility. Prior to participation, each subject was informed
of all procedures, potential risks, and benefits associated
with the study through both verbal and written form in
accordance with the procedures approved by the Uni-
versity Institutional Review Board for Human Subjects
Research. All subjects signed an informed consent form
prior be being admitted.
Screening
During the initial visit to the laboratory, subjects com-
pleted the informed consent form, health and physical
activity questionnaires. Subjects were provided with
food logs and instructions regarding how to complete
these logs during the week prior to beginning their
assigned condition and the final week of the assigned
condition (described below). Subjects also received a
detailed schedule for the entire study period mapping
out all pertinent dates of participation.
Testing
For the two visits described below, subjects reported to
the laboratory in the morning hours (5:00-10:00 am)
following a 10 hour overnight fast. After resting for
10 minutes, subjects’ heart rate and blood pressure was
measured, and a blood sample was obtained. Following
this, subjects’ height, weight, waist and hip circumfer-
ence, skinfold thickness (7 site), and body composition
was measured. Body composition was determined by
dual energy x-ray absorptiometry (DEXA; Hologic QDR-
4500W) using a 4-minute fan array. Specifically, total
and regional (trunk specific) body fat were determined.
The assessment was performed by a licensed technician.
These exact procedures were followed for both test days.
Blood Sampling and Biochemistry
Blood was collected from subjects on two different days
throughout the course of the study: pre intervention (day
1 of the study) and post intervention (day 57 of the study).
On each occasion, venous blood samples (25 mL; 5 teas-
poons) were taken from subjects via needle and Vacutai-
ner
®. Blood samples were collected in a fasted and 10
minute rested state. Following collection, samples were
processed and immediately placed in the refrigerator or
the freezer, depending on the sample. A portion of blood
samples were sent to Laboratory Corporation of America
(LabCorp) for analysis of complete blood count, compre-
hensive metabolic panel, and lipid panel. The complete
blood count was determined using an automated cell
counter (Coulter LH750). The comprehensive metabolic
panel was determined using automated procedures
(Roche/Hitachi Modular). The lipid panel was determined
using enzymatic procedures (Roche/Hitachi Modular). For
Study 1 only, insulin was determined by LabCorp using an
immuno-chemiluminescent assay procedure (Roche Mod-
ular E170) and C-reactive protein was determined using a
high-sensitivity, particle-enhanced turbidimetric immu-
noassay (Roche Integra 800). The homeostasis model
assessment (HOMA-IR) was used as an index of insulin
resistance [6] and calculated as: [fasting glucose (mg·dL
-1)
× fasting insulin (μU·mL
-1)]/405.
All remaining blood was stored at -70°C until analyzed
for outcome variables for Study 1 (resistin, adiponectin,
free fatty acids, malondialdehyde, hydrogen peroxide,
and Trolox Equivalent Antioxidant Capacity) and Study
2 (free fatty acids, malondialdehyde, insulin). Both resis-
tin and adiponectin were determined in serum using an
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the manufacturer (SPI-Bio, Berin Pharma, France). Free
fatty acids were determined in plasma using the Free
Fatty Acid Quantification Kit following the instructions
of the manufacturer (BioVision). Malondialdehyde was
determined in plasma following the procedures of
Jentzsch et al [7], using reagents purchased from North-
west Life Science Specialties (Vancouver, WA). Hydro-
gen peroxide was determined in plasma using the
Amplex Red reagent method as described by the manu-
facturer (Molecular Probes, Invitrogen Detection Tech-
nologies, Eugene, OR). Antioxidant capacity was
determined in serum using procedures outlined by the
reagent provided (Sigma Chemical, St. Louis, MO). Insu-
lin samples for Study 2 were determined in serum using
as o l i dp h a s ee n z y m el i n k e di m m u n o s o r b e n ta s s a y
(ELISA) kit following the instructions of the manufac-
turer (Calbiotech, Spring Valley, CA).
Independent Variable (Condition)
For both studies, subjects were randomly assigned in a
double-blind manner to consume either a placebo or
LFO at a dosage at 300 mg·day
-1 (taken in 3 capsules
[100 mg each] with the evening meal. Kaneka Glavo-
noid™ is a licorice derived (Glycyrrhiza glabra L.) flavo-
noid (Licorice Glabra Polyphenol) oil and used as LFO in
the present study. Glavonoid™ has been reported to
have high bioavailability [8] and to be safe in animal toxi-
cology studies, with no genotoxicity or carcinogenicity
observed. Furthermore, no clinically significant adverse
effects have been noted in humans with dosing up to 400
mg/d (delivered as 1200 mg/d of LFO) [9] and 600 mg/d
(delivered as 1800 mg/d of LFO) [10] for four weeks. The
particular flavonoids used in Glavonoid™ are specific to
the Asian licorice glabra species; hence, results from
other studies focused on LFO may not be directly com-
parable. Supposedly, this particular Asian licorice specie
has higher levels of glabridin, compared to other forms of
LFO, possibly due to the use of a double extraction
method used in the processing of Kaneka Glavonoid™.
Glavonoid™ is standardized to 30% licorice glabra poly-
phenol and 3% glabridin. The placebo (medium chain tri-
glycerides and bees wax) and Glavonoid™ capsules were
identical in appearance and were dispensed to subjects in
unlabeled bottles. Capsule counts upon bottle return
determined compliance. Subjects received their assigned
condition for a period of eight (8) weeks.
Dietary Records and Physical Activity
For both studies, subjects were instructed to maintain
their normal diet during the entire study period and to
record intake during the week prior to each test day.
The exception was the addition of the supplemental
meal used in Study 2 (described below). Diet records
were analyzed for total calories, protein, carbohydrate,
fat, and a variety of micronutrients (Food Processor
SQL, version 9.9, ESHA Research, Salem, OR). Subjects
were asked to maintain their normal physical activity
habits during the study period, with the exception of the
two days (48 hours) prior to each test day, in which
they were asked not to perform any strenuous exercise.
Supplemental Meal (Study 2 only)
In an attempt to induce an acute state of overfeeding
and body weight/fat gain, subjects in Study 2 were
required to consume a supplemental meal each day of
the intervention period. This meal was consumed prior
to bedtime (i.e., between the final daily meal and bed-
time), along with the Glavonoid™ or placebo capsules.
The meal consisted of a combination of whole milk and
a meal replacement powder (Muscle Juice™ 2544; Ulti-
mate Nutrition). All subjects consumed two cups of
whole milk (300 kilocalories), and the dosage of meal
replacement powder was based on subjects’ body weight
and equal to a combined kilocalorie load of 8 kilocal-
ories per kilogram (milk + powder). For example, a 180
pound man (82 kg) consumed an additional 656 calories
in the form of this supplemental meal/shake (300 kilo-
calories of milk + 356 kilocalories of powder). For most
subjects, this provided a kilocalorie load of approxi-
mately 25% of their daily intake. This meal was com-
prised of approximately 30% fat, 20% protein, and 50%
carbohydrate. Subjects were provided with adequate
meal replacement powder every four weeks and were
instructed to consume the supplemental meal in addi-
tion to their regular daily food and beverage intake.
Statistical Analysis
For both studies, outcome measures were analyzed using
a 2 (condition) × 2 (pre/post intervention) analysis of
variance (ANOVA). The data are presented as mean ±
SEM. All analyses were performed using JMP statistical
software (version 4.0.3, SAS Institute, Cary, NC). Statis-
tical significance was set at P ≤ 0.05.
Results
Subject compliance to treatment, descriptive characteris-
tics, anthropometric and hemodynamic data are pre-
sented in Table 1 (Study 1) and Table 2 (Study 2). In
both studies, compliance to treatment was excellent and
not different between conditions. For Study 1, no signifi-
cant interactions or main effects were noted (p > 0.05).
For Study 2, a condition effect was noted for age (p =
0.04), DEXA total body fat (p = 0.03), DEXA trunk body
fat (p = 0.05), and total fat mass (p = 0.02). No other
significant effects were noted (p > 0.05).
Complete blood count data are presented in Table 3
(Study 1) and Table 4 (Study 2). For Study 1, no
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Glavonoid™ or placebo for eight weeks
Variable Glavonoid™ Pre
(n = 11)
Glavonoid™ Post
(n = 11)
Placebo
Pre
(n = 11)
Placebo
Post
(n = 11)
Compliance to Treatment (%) NA 94.8 ± 1.4 NA 97.0 ± 1.2
Age (years) 28.4 ± 2.8 28.4 ± 2.8 25.7 ± 1.8 25.7 ± 1.8
Height (cm) 173.9 ± 3.5 173.9 ± 3.5 175.4 ± 2.8 175.4 ± 2.8
Body Weight (kg) 88.7 ± 4.0 88.6 ± 3.7 92.3 ± 2.9 92.0 ± 3.0
BMI (kg·m
-2) 29.4 ± 1.3 29.4 ± 1.2 30.2 ± 1.2 30.1 ± 1.3
Waist (cm) 88.5 ± 3.2 88.9 ± 3.0 90.7 ± 2.0 90.9 ± 2.1
Hip (cm) 113.8 ± 2.3 114.2 ± 2.3 114.6 ± 2.3 113.7 ± 2.2
Waist:Hip 0.78 ± 0.02 0.78 ± 0.02 0.79 ± 0.02 0.80 ± 0.02
DEXA Total Body Fat (%) 33.0 ± 2.9 32.7 ± 3.2 32.1 ± 2.1 32.2 ± 2.1
DEXA Trunk Body Fat (%) 34.1 ± 2.7 34.0 ± 3.2 32.8 ± 2.4 32.5 ± 2.2
Total Fat Mass (kg) 29.1 ± 2.8 28.8 ± 2.9 29.8 ± 2.4 29.7 ± 2.4
Total Fat Free Mass (kg) 59.7 ± 3.9 59.8 ± 3.9 62.5 ± 2.5 62.2 ± 2.5
Skinfold Thickness (mm) 228.7 ± 19.0 221.0 ± 16.6 231.6 ± 11.1 217.9 ± 13.2
Heart Rate (bpm) 64.8 ± 3.1 63.9 ± 2.2 66.4 ± 1.8 68.1 ± 2.7
Systolic Blood Pressure (mmHg) 114.7 ± 3.4 114.4 ± 2.8 108.9 ± 3.4 111.8 ± 2.4
Diastolic Blood Pressure (mmHg) 75.1 ± 3.2 74.9 ± 3.0 70.3 ± 2.1 73.3 ± 2.5
Values are mean ± SEM.
No condition × pre/post intervention interaction effects noted (p > 0.05).
No condition effects noted (p > 0.05).
No pre/post intervention effects noted (p > 0.05).
Table 2 Descriptive characteristics, anthropometric and hemodynamic data for 23 resistance trained men assigned to
Glavonoid™ or placebo for eight weeks
Variable Glavonoid™ Pre
(n = 12)
Glavonoid™ Post
(n = 12)
Placebo
Pre
(n = 11)
Placebo
Post
(n = 11)
Resistance Training (years) 4.3 ± 0.9 NA 5.1 ± 0.9 NA
Compliance to Treatment (%) NA 96.1 ± 1.4 NA 96.3 ± 1.0
Age (years)* 24.2 ± 1.0 24.3 ± 1.0 21.8 ± 1.3 21.9 ± 1.3
Height (cm) 178.2 ± 1.7 178.2 ± 1.7 177.4 ± 1.6 177.4 ± 1.6
Body Weight (kg) 76.2 ± 2.7 78.1 ± 2.8 75.1 ± 2.6 76.7 ± 2.7
BMI (kg·m
-2) 23.9 ± 0.6 24.5 ± 0.7 23.8 ± 0.6 24.3 ± 0.6
Waist (cm) 79.8 ± 1.2 80.8 ± 1.2 79.0 ± 1.5 80.1 ± 1.6
Hip (cm) 97.6 ± 1.5 98.2 ± 1.5 97.6 ± 1.3 97.2 ± 1.4
Waist:Hip 0.82 ± 0.0 0.82 ± 0.0 0.81 ± 0.0 0.82 ± 0.0
DEXA Total Body Fat (%)* 14.6 ± 1.1 14.9 ± 1.2 11.9 ± 1.0 12.8 ± 1.0
DEXA Trunk Body Fat (%)* 14.5 ± 1.1 14.9 ± 1.2 11.9 ± 1.1 12.9 ± 1.1
Total Fat Mass (kg)* 11.0 ± 0.7 11.5 ± 0.8 8.9 ± 0.8 9.8 ± 0.8
Total Fat Free Mass (kg) 65.1 ± 2.8 66.5 ± 2.9 66.1 ± 2.5 67.0 ± 2.6
Skinfold Thickness (mm) 82.8 ± 4.3 91.9 ± 5.7 71.9 ± 6.5 85.6 ± 8.0
Heart Rate (bpm) 62.2 ± 2.5 62.1 ± 2.4 59.9 ± 3.0 56.2 ± 3.6
Systolic Blood Pressure (mmHg) 125.1 ± 3.0 126.8 ± 2.2 122.8 ± 2.4 125.0 ± 3.4
Diastolic Blood Pressure (mmHg) 74.1 ± 3.3 75.2 ± 3.3 69.2 ± 3.7 72.5 ± 3.1
Values are mean ± SEM.
No condition × pre/post intervention interaction effects noted (p > 0.05).
* Condition effect noted for age (p = 0.04), DEXA Total Body Fat (p = 0.03), DEXA Trunk Body Fat (p = 0.05), and Total Fat Mass (p = 0.02). No other condition
effects noted (p > 0.05).
No pre/post intervention effects noted (p > 0.05).
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0.05). For Study 2, pre/post intervention effects were
noted for hematocrit (p = 0.03) and MCHC (p = 0.005).
No other significant effects were noted (p > 0.05).
Metabolic panel data are presented in Table 5 (Study
1) and Table 6 (Study 2). For Study 1, a condition ×
pre/post intervention interaction effect was noted for
sodium (p = 0.04), a condition effect was noted for
sodium (p = 0.04), and a pre/post intervention effect
was noted for AST (SGOT) (p = 0.02). No other signifi-
cant effects were noted (p > 0.05). For Study 2, a condi-
tion effect was noted for chloride (p = 0.04), Alk Phos
(p = 0.003), and ALT (SGOT) (p = 0.04). A pre/post
intervention effect was noted for CO2 (p = 0.01) and
calcium (p = 0.007). No other significant effects were
noted (p > 0.05).
Table 3 Complete blood count data for 22 men and women assigned to Glavonoid™ or placebo for eight weeks
Variable Glavonoid™ Pre
(n = 11)
Glavonoid™ Post
(n = 11)
Placebo
Pre
(n = 11)
Placebo
Post
(n = 11)
WBC (10
3· μL
-1) 5.8 ± 0.4 5.8 ± 0.4 6.6 ± 0.5 6.0 ± 0.6
RBC (10
6· μL
-1) 4.5 ± 0.1 4.4 ± 0.1 4.4 ± 0.1 4.5 ± 0.1
Hemoglobin (g·dL
-1) 13.8 ± 0.4 13.6 ± 0.3 13.5 ± 0.5 14.0 ± 0.5
Hematocrit (%) 39.7 ± 1.0 40.1 ± 1.0 39.2 ± 1.4 40.9 ± 1.4
MCV (fL) 88.7 ± 1.1 90.6 ± 1.4 90.1 ± 1.1 90.9 ± 1.6
MCH (pg) 30.7 ± 0.4 30.7 ± 0.4 31.0 ± 0.6 31.1 ± 0.5
MCHC (g·dL
-1) 34.7 ± 0.2 34.0 ± 0.2 34.5 ± 0.3 34.2 ± 0.2
RDW (%) 13.4 ± 0.2 13.5 ± 0.3 13.8 ± 0.4 13.5 ± 0.4
Platelets (10
3· μL
-1) 201.7 ± 14.2 200.9 ± 14.8 212.6 ± 20.0 215.5 ± 18.8
Neutrophils (%) 55.4 ± 1.9 58.3 ± 4.1 52.2 ± 3.0 51.2 ± 3.3
Lymphocytes (%) 33.5 ± 2.0 31.2 ± 3.6 37.4 ± 2.9 37.6 ± 3.0
Monocytes (%) 7.5 ± 0.5 6.9 ± 0.6 6.9 ± 0.8 7.3 ± 0.7
Eosinophils (%) 3.0 ± 0.6 3.1 ± 0.5 3.3 ± 0.8 3.4 ± 0.7
Basophils (%) 0.6 ± 0.2 0.5 ± 0.2 0.2 ± 0.1 0.5 ± 0.2
Values are mean ± SEM.
No condition × pre/post intervention interaction effects noted (p > 0.05).
No condition effects noted (p > 0.05).
No pre/post intervention effects noted (p > 0.05).
Table 4 Complete blood count data for 23 resistance trained men assigned to Glavonoid™ or placebo for eight weeks
Variable Glavonoid™ Pre
(n = 12)
Glavonoid™ Post
(n = 12)
Placebo
Pre
(n = 11)
Placebo
Post
(n = 11)
WBC (10
3· μL
-1) 6.7 ± 0.4 6.4 ± 0.5 6.5 ± 0.6 6.1 ± 0.4
RBC (10
6· μL
-1) 4.8 ± 0.8 4.8 ± 0.1 4.8 ± 0.1 4.9 ± 0.1
Hemoglobin (g·dL
-1) 14.9 ± 0.2 14.9 ± 0.3 15.0 ± 0.3 15.3 ± 0.2
Hematocrit (%)** 43.1 ± 0.5 44.0 ± 0.7 43.2 ± 0.7 45.3 ± 0.7
MCV (fL) 90.7 ± 1.0 91.7 ± 1.2 90.5 ± 1.1 92.2 ± 1.3
MCH (pg) 31.2 ± 0.4 31.0 ± 0.4 31.3 ± 0.4 31.2 ± 0.5
MCHC (g·dL
-1)** 34.4 ± 0.2 33.9 ± 0.2 34.6 ± 0.2 33.9 ± 0.2
RDW (%) 12.9 ± 0.2 13.0 ± 0.1 13.0 ± 0.1 13.2 ± 0.2
Platelets (10
3· μL
-1) 208.3 ± 14.1 199.5 ± 10.4 206.8 ± 13.1 206.0 ± 12.9
Neutrophils (%) 57.8 ± 2.6 56.6 ± 2.9 57.8 ± 2.8 58.1 ± 2.5
Lymphocytes (%) 31.4 ± 2.4 33.0 ± 2.6 30.8 ± 2.6 30.7 ± 2.2
Monocytes (%) 7.9 ± 0.4 7.6 ± 0.5 8.5 ± 0.6 7.3 ± 0.6
Eosinophils (%) 2.5 ± 0.4 2.8 ± 0.4 2.5 ± 0.3 3.4 ± 0.8
Basophils (%) 0.3 ± 0.1 0.3 ± 0.0 0.4 ± 0.2 0.5 ± 0.2
Values are mean ± SEM.
No condition × pre/post intervention interaction effects noted (p > 0.05).
No condition effects noted (p > 0.05).
** Pre/post intervention effect noted for Hematocrit (p = 0.03) and MCHC (p = 0.005). No other pre/post intervention effects noted (p > 0.05).
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Table 7 (Study 1) and Table 8 (Study 2; in addition to
malondialdehyde data). For Study 1, no significant inter-
actions or main effects were noted (p > 0.05). For Study
2, a pre/post intervention effect was noted for choles-
terol (p = 0.02) and LDL-C (p = 0.03). No other signifi-
cant effects were noted (p > 0.05).
Oxidative stress and inflammatory related data for Study 1
are presented in Table 9. No significant interactions or main
effects were noted (p > 0.05). Table 10 presents percent
change data for selected variables of interest in Study 2. The
difference between Glavonoid™ and placebo for cholesterol
(p = 0.09), triglycerides (p = 0.20), LDL-C (p = 0.19), and
DEXA total body fat (p = 0.21) approached statistical
significance.
Dietary intake data are presented in Table 11 (Study 1)
and Table 12 (Study 2). For Study 1, a condition effect was
noted for vitamin A (p = 0.05). No other significant effects
were noted (p > 0.05). For Study 2, a condition effect was
noted for kilocalories (p = 0.002), protein (p = 0.02), carbo-
hydrate (p = 0.02), fat (p = 0.002), and saturated fat (p =
0.004). No other significant effects were noted (p > 0.05).
Discussion
The findings from our dual investigation of the effect of
the dietary supplement Glavonoid™ indicate the follow-
ing: In a sample of overweight to grade I-II obese men
and women or a sample of athletic men consuming a
daily supplemental meal, Glavonoid™ treatment at a
dosage of 300 mg·day
-1 over a period of eight weeks does
not result in any statistically significant difference in
anthropometric or biochemical markers of health and
adiposity as compared to a placebo. However, when
investigating percent change from baseline data (pre
intervention to post intervention) in Study 2, subjects in
the Glavonoid™ condition did experience less overall fat
gain, as well as attenuation in the elevation in selected
blood lipids (e.g., cholesterol, LDL-C, and triglycerides;
Table 10). While these differences failed to reach statisti-
cal significance, it is possible that Glavonoid™ supple-
mentation may provide some benefit to certain
individuals engaged in a period of overfeeding. The sup-
plemental meal used in the present study consisted of
approximately 30% fat, 20% protein, and 50% carbohy-
drate, providing subjects an additional 8 kilocalories per
Table 5 Metabolic panel data for 22 men and women assigned to Glavonoid™ or placebo for eight weeks
Variable Glavonoid™ Pre
(n = 11)
Glavonoid™ Post
(n = 11)
Placebo
Pre
(n = 11)
Placebo
Post
(n = 11)
Insulin (μU·mL
-1) 7.9 ± 1.3 9.2 ± 1.5 9.1 ± 0.5 8.4 ± 1.2
HOMA-IR 1.6 ± 0.3 2.0 ± 0.4 1.9 ± 0.1 1.9 ± 0.3
Adiponectin (μg·mL
-1) 17.8 ± 1.7 19.0 ± 2.7 15.3 ± 3.4 15.3 ± 3.2
Resistin (ng·mL
-1) 5.7 ± 0.4 5.9 ± 0.6 5.1 ± 0.7 4.8 ± 0.5
Glucose (mg·dL
-1) 84.4 ± 1.9 85.7 ± 2.9 83.4 ± 2.7 88.0 ± 4.2
BUN (mg·dL
-1) 13.6 ± 1.2 12.6 ± 1.3 12.7 ± 1.0 13.8 ± 1.3
Creatinine (mg·dL
-1) 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.0 0.9 ± 0.0
BUN:Creatinine 14.2 ± 0.8 13.1 ± 0.6 14.3 ± 1.5 15.0 ± 1.6
Sodium (mmol·L
-1)*† 137.5 ± 0.4 139.0 ± 0.5 138.9 ± 0.5 139.0 ± 0.5
Potassium (mmol·L
-1) 4.1 ± 0.1 4.2 ± 0.1 4.3 ± 0.1 4.5 ± 0.2
Chloride (mmol·L
-1) 102.5 ± 1.1 102.1 ± 0.7 102.7 ± 0.6 103.1 ± 0.5
CO2 (mmol·L
-1) 24.0 ± 0.9 26.0 ± 0.8 24.3 ± 0.7 25.3 ± 0.7
Calcium (mg·dL
-1) 9.4 ± 0.1 9.2 ± 0.1 9.4 ± 0.2 9.1 ± 0.1
Protein (g·dL
-1) 6.9 ± 0.1 6.9 ± 0.1 6.9 ± 0.1 7.0 ± 0.1
Albumin (g·dL
-1) 4.3 ± 0.1 4.3 ± 0.1 4.3 ± 0.1 4.3 ± 0.1
Globulin (g·dL
-1) 2.6 ± 0.1 2.6 ± 0.1 2.6 ± 0.1 2.7 ± 0.1
A:G 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1
Bilirubin (mg·dL
-1) 0.5 ± 0.1 0.4 ± 0.1 0.6 ± 0.1 0.5 ± 0.1
Alk Phos (IU·L
-1) 67.5 ± 6.8 65.3 ± 6.5 72.6 ± 6.3 70.9 ± 7.4
AST (SGOT) (IU·L
-1)** 23.7 ± 2.5 26.7 ± 2.3 21.2 ± 2.1 19.9 ± 0.9
ALT (SGPT) (IU·L
-1) 23.5 ± 4.0 28.9 ± 5.2 20.5 ± 3.9 21.2 ± 4.9
Values are mean ± SEM.
† Condition × pre/post intervention interaction effect noted for Sodium (p = 0.04). No other condition × pre/post intervention interaction effects noted
(p > 0.05).
* Condition effect noted for Sodium (p = 0.04). No other condition effects noted (p > 0.05).
** Pre/post intervention effect noted for AST (SGOT) (p = 0.02). No other pre/post intervention effects noted (p > 0.05).
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Page 6 of 10kilogram of body mass, resulting in a mean weight gain of
only ~2 kilograms. It is possible that Glavonoid™ supple-
mentation could provide greater benefit to individuals
regularly consuming higher amounts of dietary fat, or to
individuals who routinely overfeed on kilocalorie loads in
excess of what was provided in the present study. Of
course, additional investigation is needed to confirm such
a hypothesis.
Prior animal studies have noted that LFO has the cap-
ability of reducing abdominal fat when animals are sub-
jected to high fat feedings [4,11]. Nakagawa and
coworkers studied the effect of licorice flavonoids on
both abdominal fat and blood glucose regulation in
o b e s ef e m a l ed i a b e t i cK K - A
y mice and noted attenuated
fat/weight gain and increased blood glucose levels com-
pared to the control animals [2]. Collective, although
Table 6 Metabolic panel data for 23 resistance trained men assigned to Glavonoid™ or placebo for eight weeks
Variable Glavonoid™ Pre
(n = 12)
Glavonoid™ Post
(n = 12)
Placebo
Pre
(n = 11)
Placebo
Post
(n = 11)
Insulin (μU·mL
-1) 3.4 ± 0.2 3.5 ± 0.2 3.4 ± 0.1 3.6 ± 0.2
HOMA-IR 0.7 ± 0.0 0.8 ± 0.0 0.7 ± 0.1 0.8 ± 0.1
Glucose (mg·dL
-1) 88.5 ± 2.7 93.8 ± 1.3 87.3 ± 3.2 89.3 ± 2.1
BUN (mg·dL
-1) 18.8 ± 1.6 18.3 ± 1.2 17.9 ± 1.2 19.4 ± 1.4
Creatinine (mg·dL
-1) 1.2 ± 0.1 1.1 ± 0.0 1.1 ± 0.0 1.1 ± 0.0
BUN:Creatinine 16.4 ± 1.4 16.7 ± 0.9 16.4 ± 1.1 18.4 ± 1.4
Sodium (mmol·L
-1) 140.1 ± 0.7 140.6 ± 0.8 139.7 ± 0.6 139.0 ± 1.0
Potassium (mmol·L
-1) 4.4 ± 0.1 4.5 ± 0.1 4.3 ± 0.1 4.4 ± 0.1
Chloride (mmol·L
-1)* 101.1 ± 0.7 101.2 ± 0.6 101.5 ± 0.5 99.5 ± 0.8
CO2 (mmol·L
-1)** 24.6 ± 0.6 26.3 ± 0.4 25.5 ± 0.8 27.0 ± 0.5
Calcium (mg·dL
-1)** 9.8 ± 0.1 9.5 ± 0.1 9.6 ± 0.1 9.5 ± 0.1
Protein (g·dL
-1) 7.1 ± 0.1 7.1 ± 0.1 6.9 ± 0.1 7.2 ± 0.1
Albumin (g·dL
-1) 4.5 ± 0.1 4.6 ± 0.1 4.4 ± 0.1 4.6 ± 0.1
Globulin (g·dL
-1) 2.6 ± 0.1 2.6 ± 0.1 2.4 ± 0.1 2.6 ± 0.1
A:G 1.8 ± 0.1 1.8 ± 0.1 1.9 ± 0.1 1.8 ± 0.1
Bilirubin (mg·dL
-1) 0.8 ± 0.2 0.6 ± 0.1 0.6 ± 0.1 0.7 ± 0.1
Alk Phos (IU·L
-1)* 70.4 ± 5.0 71.2 ± 4.2 83.0 ± 3.3 84.5 ± 3.3
AST (SGOT) (IU·L
-1) 25.8 ± 3.4 27.8 ± 3.1 30.0 ± 4.2 26.7 ± 2.1
ALT (SGPT) (IU·L
-1)* 20.3 ± 1.9 21.0 ± 2.2 27.3 ± 2.5 26.7 ± 4.5
Values are mean ± SEM.
No significant condition × pre/post intervention interaction effects noted (p > 0.05).
* Condition effect noted for Chloride (p = 0.04), Alk Phos (p = 0.003), and ALT (SGOT) (p = 0.04). No other condition effects noted (p > 0.05).
** Pre/post intervention effect noted for CO2 (p = 0.01) and Calcium (p = 0.007). No other pre/post intervention effects noted (p > 0.05).
Note: Insulin and HOMA-IR data missing for one subject in Glavonoid™ condition (n = 11).
Table 7 Lipid panel data for 22 men and women assigned to Glavonoid™ or placebo for eight weeks
Variable Glavonoid™ Pre
(n = 11)
Glavonoid™ Post
(n = 11)
Placebo
Pre
(n = 11)
Placebo
Post
(n = 11)
Cholesterol (mg·dL
-1) 184.5 ± 11.8 174.2 ± 10.2 158.4 ± 10.2 168.3 ± 12.9
Triglycerides (mg·dL
-1) 113.8 ± 16.8 98.2 ± 17.8 79.3 ± 16.6 71.0 ± 17.3
HDL-C (mg·dL
-1) 52.7 ± 3.1 52.8 ± 3.7 47.6 ± 6.3 48.0 ± 4.5
VLDL-C (mg·dL
-1) 22.7 ± 3.3 19.6 ± 3.5 16.0 ± 3.3 14.1 ± 3.4
LDL-C (mg·dL
-1) 109.1 ± 10.5 101.7 ± 9.2 94.8 ± 7.9 106.2 ± 11.0
LDL-C/HDL-C 2.2 ± 0.3 2.1 ± 0.3 2.3 ± 0.4 2.4 ± 0.4
Total:HDL-C 3.7 ± 0.4 3.5 ± 0.4 3.8 ± 0.5 3.8 ± 0.5
Free Fatty Acids (mmol·L
-1) 0.33 ± 0.05 0.36 ± 0.04 0.30 ± 0.04 0.23 ± 0.04
Values are mean ± SEM.
No condition × pre/post intervention interaction effects noted (p > 0.05).
No condition effects noted (p > 0.05).
No pre/post intervention effects noted (p > 0.05).
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Page 7 of 10few studies are available in regards to LFO, the animal
literature does support the role of LFO in attenuating
abdominal adiposity. Of course, the controlled nature of
such experiments allows for low variability in response
between animals, increasing the chances of detecting
statistically significant findings. Coupled with the fact
that the animals used in the above studies were exclu-
sively obese (as compared to subjects in Study 1 who
were mostly overweight or grade I obese), confounding
factors such as dietary and physical activity (which are
controlled in animal experiments but cannot be totally
controlled in human studies) may account for some of
the discrepancies between our findings and those of the
animal studies.
That being said, there are at least two human trials using
LFO that have noted significant findings in regards to
decreasing adiposity. For example, Tominaga et al. noted a
significant decrease (~1 kg) in total body fat mass when
overweight subjects were supplemented LFO at a daily
dosage of 300 mg, 600 mg, or 900 mg for 8 weeks [3].
These data are conflicted with those presented herein, and
might be partly explained by the fact that subjects in the
Tominaga et al. study were not involved in an exercise
program during the course of the study, compared to sub-
jects in the present investigation who were all active. It is
possible that subjects in the present study may have
altered their activity habits during the course of their parti-
cipation, confounding the effect of the assigned condition.
Unfortunately, when working with human subjects in a
free-living environment, such possibilities exist. Tominaga
and colleagues performed a similar investigation, noting
significant reductions in body mass, attributed to body fat
mass, when subjects ingested 300 mg/day of LFO com-
pared to a placebo for 12 weeks [10]. Finally, one other
investigation using LFO noted increased resistance of LDL
to atherogenic modifications, decreased plasma lipid levels,
and decreased systolic blood pressure in patients with
hypercholesterolemia [12].
In relation to the above, while we failed to note any
statistically significant change in serum lipids following
Glavonoid™ treatment, our subjects did not have diag-
nosed hypercholesterolemia. It is possible that differing
results would have been noted in the present study if
we had purposely recruited individuals with elevated
Table 8 Lipid panel data for 23 resistance trained men assigned to Glavonoid™ or placebo for eight weeks
Variable Glavonoid™ Pre
(n = 12)
Glavonoid™ Post
(n = 12)
Placebo
Pre
(n = 11)
Placebo
Post
(n = 11)
Cholesterol (mg·dL
-1)** 147.9 ± 6.4 159.8 ± 8.0 148.4 ± 7.0 178.7 ± 11.6
Triglycerides (mg·dL
-1) 76.6 ± 10.4 81.3 ± 10.6 76.4 ± 10.7 95.8 ± 8.9
HDL-C (mg·dL
-1) 48.0 ± 2.2 47.8 ± 2.4 47.9 ± 2.1 50.0 ± 2.7
VLDL-C (mg·dL
-1) 15.4 ± 2.1 16.3 ± 2.2 15.3 ± 2.2 19.3 ± 1.8
LDL-C (mg·dL
-1)** 84.5 ± 6.2 95.7 ± 8.1 85.2 ± 5.7 109.5 ± 10.0
LDL-C/HDL-C 1.8 ± 0.2 2.1 ± 0.2 1.8 ± 0.2 2.2 ± 0.2
Total:HDL-C 3.1 ± 0.2 3.5 ± 0.3 3.2 ± 0.2 3.6 ± 0.2
Free Fatty Acids (mmol·L
-1) 0.41 ± 0.1 0.30 ± 0.0 0.30 ± 0.0 0.32 ± 0.1
Malondialdehyde (μmol·L
-1) 0.88 ± 0.09 0.84 ± 0.08 0.87 ± 0.11 0.84 ± 0.09
Values are mean ± SEM.
No significant condition × pre/post intervention interaction effects noted (p > 0.05).
No condition effects noted (p > 0.05).
** Significant pre/post intervention effect noted for Cholesterol (p = 0.02) and LDL-C (p = 0.03). No other pre/post intervention effects noted (p > 0.05).
Table 9 Oxidative stress and inflammatory related variables for 22 men and women assigned to Glavonoid™ or
placebo for eight weeks
Variable Glavonoid™ Pre
(n = 11)
Glavonoid™ Post
(n = 11)
Placebo
Pre
(n = 11)
Placebo
Post
(n = 11)
Malondialdehyde (μmol·L
-1) 0.95 ± 0.14 0.70 ± 0.11 0.67 ± 0.05 0.66 ± 0.08
Hydrogen Peroxide (μmol·L
-1) 6.86 ± 1.15 5.24 ± 0.82 4.83 ± 0.66 4.11 ± 0.48
Trolox Equivalent Antioxidant Capacity (mmol·L
-1) 0.68 ± 0.01 0.63 ± 0.03 0.66 ± 0.02 0.68 ± 0.00
C-Reactive Protein
(ng·mL
-1)
3.86 ± 1.35 3.29 ± 0.93 2.90 ± 1.02 2.02 ± 1.11
Values are mean ± SEM.
No condition × pre/post intervention interaction effects noted (p > 0.05).
No condition effects noted (p > 0.05).
No pre/post intervention effects noted (p > 0.05).
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healthy, and regularly performed structured exercise.
This was not the case in the other trials, as subjects in
the Tominaga and co-workers studies consisted of both
men and women (post menopausal in one study), aged
24-64 years [3]. Finally, as our sample size was relatively
small compared to the other human trials, including
additional subjects would have increased our statistical
power in detecting an effect in our chosen outcome
measures.
It is worth noting that the Glavonoid™ treatment was
well-tolerated by subjects and did not result in any
adverse outcomes as related to the measured outcome
parameters. These findings confirm previous reports in
both animals [13,14] and man [9,10] indicating no
adverse outcomes with chronic ingestion of LFO.
Conclusion
In conclusion, our findings do not support prior data
pertaining to LFO supplementation in animal and
human subjects, as we did not detect any changes of
statistical significance with Glavonoid™ treatment at a
dosage of 300 mg·day
-1 over a period of eight weeks. It
is possible that a higher dosage or longer duration of
treatment of Glavonoid™ supplementation could pro-
vide benefit to individuals, or that the effects of Glavo-
noid™ m a yb em o r ep r o n o u n c e di nah o m o g e n o u s
sample of grade II and grade III obese individuals.
Moreover, the use of difference assessment tools may
allow for more precision in testing certain outcome
measures (e.g., CT scans vs. DEXA scans). Additional
investigation is needed to confirm such hypotheses.
Finally, the Glavonoid™ treatment was well-tolerated by
subjects and did not result in any adverse outcomes as
related to the measured outcome parameters.
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Cholesterol 8.3 ± 3.5 21.0 ± 6.5 0.09
Triglycerides 13.2 ± 14.8 42.5 ± 16.9 0.20
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DEXA Total Body Fat 2.0 ± 3.0 7.3 ± 2.7 0.21
DEXA Trunk Body Fat 3.1 ± 4.0 10.2 ± 4.6 0.26
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Values are mean ± SEM.
Table 11 Dietary intake for 22 men and women assigned to Glavonoid™ or placebo before and during the final week
of an eight week intervention
Variable Glavonoid™ Pre
(n = 11)
Glavonoid™ Post
(n = 11)
Placebo
Pre
(n = 11)
Placebo
Post
(n = 11)
Kilocalories 2230 ± 213 2045 ± 208 1976 ± 162 2052 ± 180
Protein (g) 96 ± 10 95 ± 11 82 ± 8 84 ± 5
Carbohydrate (g) 279 ± 25 231 ± 22 251 ± 24 263 ± 31
Fiber (g) 21 ± 2 15 ± 1 15 ± 2 15 ± 2
Sugar (g) 95 ± 9 74 ± 9 92 ± 11 98 ± 17
Fat (g) 76 ± 9 75 ± 10 71 ± 5 73 ± 5
Saturated Fat (g) 25 ± 4 25 ± 4 22 ± 2 25 ± 2
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Vitamin A (RE)* 502 ± 169 399 ± 95 221 ± 57 256 ± 5313
Selenium (μg) 47 ± 55 ± 10 47 ± 8 46 ± 5
Values are mean ± SEM.
No significant condition × pre/post intervention interaction effects noted (p > 0.05).
* Condition effect noted for vitamin A (p = 0.05). No other condition effects noted (p > 0.05).
No significant pre/post intervention effects noted (p > 0.05).
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Table 12 Dietary intake for 22 resistance trained men assigned to Glavonoid™ or placebo before and during the final
week of an eight week intervention
Variable Glavonoid™ Pre
(n = 12)
Glavonoid™ Post
(n = 12)
Placebo
Pre
(n = 10)
Placebo
Post
(n = 10)
Kilocalories* 2233 ± 141 2469 ± 185 3082 ± 295 3252 ± 336
Protein (g)* 117 ± 11 130 ± 12 154 ± 17 170 ± 22
Carbohydrate (g)* 269 ± 22 316 ± 39 372 ± 41 382 ± 42
Fiber (g) 21 ± 2 22 ± 2 22 ± 3 20 ± 2
Sugar (g) 118 ± 20 143 ± 37 157 ± 32 163 ± 20
Fat (g)* 75 ± 9 78 ± 6 114 ± 15 110 ± 13
Saturated Fat (g)* 23 ± 3 26 ± 3 38 ± 7 38 ± 6
Monounsaturated Fat (g) 16 ± 5 14 ± 2 17 ± 4 20 ± 4
Polyunsaturated Fat (g) 7 ± 2 5 ± 1 7 ± 2 7 ± 1
Trans Fat (g) 1 ± 0 1 ± 1 1 ± 0 1 ± 0
Cholesterol (mg) 477 ± 72 404 ± 61 478 ± 76 541 ± 95
Vitamin C (mg) 111 ± 18 103 ± 19 73 ± 11 93 ± 16
Vitamin E (mg) 11 ± 2 10 ± 2 10 ± 2 17 ± 5
Vitamin A (RE) 410 ± 115 338 ± 86 307 ± 59 472 ± 104
Selenium (μg) 77 ± 17 74 ± 13 70 ± 12 104 ± 23
Values are mean ± SEM.
No significant condition × pre/post intervention interaction effects noted (p > 0.05).
* Condition effect noted for kilocalories (p = 0.002), protein (p = 0.02), carbohydrate (p = 0.02), fat (p = 0.002), and saturated fat (p = 0.004). No other condition
effects noted (p > 0.05).
No significant pre/post intervention effects noted (p > 0.05).
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